ATOPIC DERMATITIS

This early-stage study tests whether a new combination of two experimental drugs (APG777 and APG990) is safe and how the body processes them in adults with moderate-to-severe atopic dermatitis (eczema). About 86 participants will receive either the new combo or an existing treatm…

This study tests whether a daily pill called upadacitinib, when used with steroid creams, can safely reduce eczema symptoms like itching and skin redness in teens and adults with moderate to severe disease. About 1,500 participants took the drug or a placebo for 16 weeks. The mai…

This study looks at how well the medication upadacitinib (RINVOQ) controls moderate to severe eczema (atopic dermatitis) over two years in everyday medical practice. About 634 teenagers and adults in Germany will be observed after starting the drug as prescribed by their doctor. …

This study tests whether baricitinib, a daily pill, can safely improve moderate to severe eczema in children and teens aged 2 to 17. About 516 participants will receive either baricitinib or a placebo for up to 16 weeks. The goal is to see clearer skin and less itching, with resu…

This study tests an experimental pill called jaktinib for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment …

This study looks at how safe and effective the drug CIBINQO is for treating atopic dermatitis (a type of eczema) in Japanese patients. Over 1,100 participants are being followed to track side effects and how well the drug clears skin. The goal is to see how the medicine works in …

This study tests an experimental injection called TQH2722 in 500 adults with moderate to severe atopic dermatitis (eczema). Half receive the drug, half a placebo, and neither they nor their doctors know which. The goal is to see if the drug safely reduces skin redness, itching, a…

This study tests an experimental drug, GIA632, in 34 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can clear or nearly clear the skin compared to a placebo. Participants receive either the drug or a placebo, and neither they nor their doctors…

This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear the skin. Participants receive the drug and are monitored for side effects and improvements in eczema severity.

This study tests a medicine called lebrikizumab in children aged 6 months to under 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either t…

This study tests whether people with controlled atopic dermatitis (eczema) can safely take dupilumab less often without losing control of their disease. About 256 teens and adults who have been on the standard every-2-week dose for at least a year will either stay on that schedul…

This study tests a new gel called HY209 for people with mild to moderate atopic dermatitis (eczema). About 210 adults will use the gel or a placebo to see if it improves their skin condition. The goal is to find a safe and effective treatment to control eczema symptoms.

This study tests a new medicine, Afimkibart, for people with moderate to severe eczema (atopic dermatitis). About 160 adults will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure at least a 75% improvem…

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a previous lebrikizumab study will receive the drug for up to 68 weeks,…

This study tests whether a daily pill called upadacitinib, taken along with steroid cream, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo for 12 weeks, then all will get the drug for up to a …

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 adults will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. The goal is to see if it safely reduces skin redness…

This study tests a new medicine called lebrikizumab, given alone or with steroid creams, for people with moderate-to-severe eczema (atopic dermatitis). About 301 adults will receive either the drug or a placebo for up to 62 weeks. The goal is to see if it safely reduces skin redn…

This study tests whether an experimental drug, TRIV-509, can help adults with moderate to severe atopic dermatitis (eczema). About 95 participants will receive either TRIV-509 or a placebo for 16 weeks, then switch to the other treatment. The goal is to see if the drug improves s…

This study is testing the long-term safety and effectiveness of an experimental drug called rocatinlimab for people with moderate-to-severe eczema. It involves over 2,600 adults and adolescents who previously participated in earlier rocatinlimab studies. The research aims to see …

This study tests whether a special skin care routine can prevent food allergies in infants who develop eczema by 12 weeks old. About 400 babies will use a barrier cream and an anti-inflammatory cream twice daily, compared to standard care. The goal is to see if this proactive app…

This study tested whether Bodewell eczema products can safely improve skin and quality of life in adults with atopic dermatitis (eczema). Fifteen participants used the topical products for 12 weeks. Researchers measured changes in skin severity and daily life impact.

This study tests an investigational drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). About 131 participants will receive either a low dose, high dose, or placebo to see if it reduces itching and clears skin over 16 weeks. The goal is to find…

This study tests whether a new daily pill, PF-08049820, can safely reduce itching and rash in adults with moderate to severe eczema. About 200 participants will take either the study drug or a placebo for 12 weeks, with regular checkups to track skin improvement. The goal is to s…

This study tests a new medicine called APG777 for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with creams. About 470 adults will receive either the drug or a placebo to see if it safely reduces skin redness, itching, and rash. The trial lasts up…

This early study tests a special microbubble bath (Thera-Clean) that uses no chemicals to clean skin, reduce itch, and help wounds heal. About 20 people aged 2 and older with epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis will use the bath at home for 8 weeks.…

This study looks at how well methotrexate works for people with hand eczema, a long-lasting skin condition that can seriously affect daily life. Researchers will track 50 patients starting methotrexate to see if it improves their symptoms and quality of life, and note any side ef…

This study tests whether adding narrowband UVB phototherapy (a type of light treatment) to standard topical creams helps adults with moderate eczema more than using creams alone. About 316 adults whose eczema is not well controlled by creams will be randomly assigned to receive e…

This study tests a new drug called ATI-045 in 110 adults with moderate-to-severe atopic dermatitis (eczema). Half receive the drug, half receive a placebo, and neither the patients nor doctors know who gets which. The main goal is to see if ATI-045 reduces eczema severity and itc…

This early-stage study tests a new ointment called CU-10101 in 64 people—first in healthy volunteers, then in those with mild-to-moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the ointment, not yet to prove it works. Participants ar…

This study looks at how the immune system behaves in the blood of people with moderate-to-severe atopic dermatitis (eczema). Researchers will collect blood samples from 11 adults and stimulate them in a lab to measure immune signals. The goal is to better understand the disease a…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) in Spain who are starting treatment with dupilumab. Researchers will observe how the medicine is used in real-world clinics and track its effectiveness and safety over two years. No e…

This study is creating a large registry of 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants in regular clinics to see how well current and new treatments work and what side effects occur. The g…

This early-stage study involves 160 healthy adults aged 18–55 to see how well the body absorbs an experimental drug (SHR-1819) when given through different injection devices. The drug is being developed for atopic dermatitis (eczema), but this trial does not treat the condition—i…

This study looks for specific gene changes (filaggrin mutations) in 300 Latinx adults with eczema. Researchers want to understand how these gene changes relate to the disease in this group. The goal is to learn more, not to test a new treatment.

This study follows 2,500 children from before birth up to age 3 (or 6 if they choose) to learn what causes food allergies and eczema. Researchers collect samples and track health to find early warning signs and biological pathways. The goal is to better understand these condition…

This study looks at how a new medicine for atopic dermatitis (eczema) called PF-08049820 affects the way other drugs work in the body. It involves 16 healthy adult women who will take the new medicine along with birth control pills, a sedative, and a blood thinner. The goal is to…

This study looks at skin and blood samples from 505 children with eczema (atopic dermatitis) to find biological markers that explain the disease. Researchers compare these markers to those in adults to better understand what causes eczema in kids. No new treatments are tested; th…

This study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream. Researchers are watching for any long-term cancer risks over 10 years. No new treatment is given—this is an observation-only registry to better understand the cream's safety.

This study is creating a large national registry of 10,000 adults with atopic dermatitis (eczema) to track their health over time. Its main purpose is to compare the real-world safety and effectiveness of different approved eczema medications that people are already using. Resear…